Reference health
Altered expression of insulin‐degrading enzyme and regulator of calcineurin in the rat intracerebral streptozotocin model and human apolipoprotein E‐ε4–associated Alzheimer's disease
131/131 checkable references clean · checked 2026-07-22
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
10 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 131 checked references that resolve
resolves10.1074/jbc.M109.011015
Insulin Receptor Dysfunction Impairs Cellular Clearance of Neurotoxic Oligomeric Aβ
resolves10.1016/j.arr.2011.01.001
Insulin-resistant brain state: The culprit in sporadic Alzheimer's disease?
resolves10.1007/s007020050067
Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis
resolves10.3233/JAD-2005-8304
Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: Link to brain reductions in acetylcholine
resolves10.3233/JAD-2005-7107
Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease – is this type 3 diabetes?
resolves10.1016/j.jalz.2006.05.197
O3–02–02: Expression of pIRS–1 (S312 and S616) is elevated in MCI and AD and correlates with cognitive impairment and neurofibrillary pathology
resolves10.1007/978-3-211-73574-9_28
Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach
resolves10.3233/JAD-2009-1115
Nitrosamine Exposure Causes Insulin Resistance Diseases: Relevance to Type 2 Diabetes Mellitus, Non-Alcoholic Steatohepatitis, and Alzheimer's Disease
resolves10.1016/j.neurobiolaging.2008.04.002
Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling
resolves10.3233/JAD-2011-101392
Dementia, Diabetes, Alzheimer's Disease, and Insulin Resistance in the Brain: Progress, Dilemmas, New Opportunities, and a Hypothesis to Tackle Intersecting Epidemics
resolves10.1002/path.2912
Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes
resolves10.2174/156720512799015037
Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
resolves10.2165/11597760-000000000-00000
Contributions of Brain Insulin Resistance and Deficiency in Amyloid-Related Neurodegeneration in Alzheimerʼs Disease
resolves10.1007/s40265-016-0674-0
Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer’s Disease
resolves10.3233/JAD-150379
Impact of Insulin Degrading Enzyme and Neprilysin in Alzheimer’s Disease Biology: Characterization of Putative Cognates for Therapeutic Applications
resolves10.1016/j.tem.2015.11.003
Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus
resolves10.1016/j.freeradbiomed.2013.01.016
Chronic high levels of the RCAN1-1 protein may promote neurodegeneration and Alzheimer disease
resolves10.1016/j.freeradbiomed.2015.02.028
Molecular mechanisms linking amyloid β toxicity and Tau hyperphosphorylation in Alzheimer׳s disease
resolves10.1111/1440-1681.12884
The neuronal and endocrine roles of <scp>RCAN</scp>1 in health and disease
resolves10.1007/s12035-014-8704-y
Aberrant Expression of RCAN1 in Alzheimer’s Pathogenesis: A New Molecular Mechanism and a Novel Drug Target
resolves10.1073/pnas.0230450100
Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain
<i>in vivo</i>
resolves10.1074/jbc.M609168200
Decreased Catalytic Activity of the Insulin-degrading Enzyme in Chromosome 10-Linked Alzheimer Disease Families
resolves10.1016/j.neurobiolaging.2010.07.005
Association between variants in IDE-KIF11-HHEX and plasma amyloid β levels
resolves10.1210/en.132.2.604
Insulin-degrading enzyme is differentially expressed and developmentally regulated in various rat tissues
resolves10.1073/pnas.92.9.3859
Degradation of the cleaved leader peptide of thiolase by a peroxisomal proteinase.
resolves10.1042/BJ20041081
Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria
resolves10.1074/jbc.273.49.32730
Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation
resolves10.1523/JNEUROSCI.20-05-01657.2000
Neurons Regulate Extracellular Levels of Amyloid β-Protein via Proteolysis by Insulin-Degrading Enzyme
resolves10.1016/0014-5793(94)00387-4
Alzheimer's β‐amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme
resolves10.1080/10409238.2017.1337707
Multiple functions of insulin-degrading enzyme: a metabolic crosslight?
resolves10.1016/j.neurobiolaging.2005.01.004
Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimer's disease: review and hypothesis
resolves10.1042/BSR20171284
GLP-1 receptor regulates cell growth through regulating IDE expression level in Aβ1–42-treated PC12 cells
resolves10.2174/18715273113126660139
Insulin-Degrading Enzyme: A Link Between Alzheimer’s and Type 2 Diabetes Mellitus
resolves10.1016/j.neulet.2017.12.025
Long-term treadmill exercise attenuates Aβ burdens and astrocyte activation in APP/PS1 mouse model of Alzheimer’s disease
resolves10.1016/j.neuroscience.2018.06.018
Insulin-signaling Pathway Regulates the Degradation of Amyloid β-protein via Astrocytes
resolves10.3233/JAD-2006-10113
Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: Relevance to Alzheimer's disease
resolves10.3233/JAD-2006-9102
Intracerebral streptozotocin model of type 3 diabetes: Relevance to sporadic Alzheimer's disease
resolves10.4172/2161-0460.1000238
Targeting Alzheimer's Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Dise ase Pathologies
resolves10.3233/JAD-160656
Improved Brain Insulin/IGF Signaling and Reduced Neuroinflammation with T3D-959 in an Experimental Model of Sporadic Alzheimer’s Disease
resolves10.1021/acschemneuro.8b00334
Altered Processing of β-Amyloid in SH-SY5Y Cells Induced by Model Senescent Microglia
resolves10.1074/jbc.M102829200
Chronic Overexpression of the Calcineurin Inhibitory Gene DSCR1 (Adapt78)Is Associated with Alzheimer's Disease
resolves10.1006/geno.1997.4866
Genomic Organization, Alternative Splicing, and Expression Patterns of theDSCR1(Down Syndrome Candidate Region 1) Gene
resolves10.1096/fj.06-7246com
Renaming the
<i>DSCR1 / Adapt78</i>
gene family as
<i>RCAN</i>
: regulators of calcineurin
resolves10.1074/jbc.275.12.8719
A Protein Encoded within the Down Syndrome Critical Region Is Enriched in Striated Muscles and Inhibits Calcineurin Signaling
resolves10.1080/1521654031000066820
DSCR1(Adapt78)‐‐A Janus Gene Providing Stress Protection but Causing Alzheimer's Disease?
resolves10.1096/fj.01-0846com
The
<i>DSCR1</i>
(
<i>Adapt78</i>
) isoform 1 protein calcipressin 1 inhibits calcineurin and protects against acute calcium‐mediated stress damage, including transient oxidative stress
resolves10.1097/00005072-199608000-00008
Reduction of Calcineurin Enzymatic Activity in Alzheimerʼs Disease: Correlation with Neuropathologic Changes
resolves10.1046/j.1471-4159.1997.68041668.x
Cytoskeletal Changes in the Brains of Mice Lacking Calcineurin Aα
resolves10.3233/JAD-2005-8108
Expression of calcipressin1, an inhibitor of the phosphatase calcineurin, is altered with aging and Alzheimer's disease
resolves10.1097/00005072-199009000-00006
Small Cerebral Hemispheres in Adults with Downʼs Syndrome: Contributions of Developmental Arrest and Lesions of Alzheimerʼs Disease
resolves10.1111/j.1471-4159.2011.07447.x
Dysregulated phosphorylation of Ca<sup>2+</sup>/calmodulin‐dependent protein kinase II‐α in the hippocampus of subjects with mild cognitive impairment and Alzheimer’s disease
resolves10.1016/j.bbr.2008.12.034
Intermediate- and long-term recognition memory deficits in Tg2576 mice are reversed with acute calcineurin inhibition
resolves10.1002/jnr.22445
Amyloid‐β oligomers impair fear conditioned memory in a calcineurin‐dependent fashion in mice
resolves10.1016/j.neulet.2010.10.033
Calcineurin inhibition with systemic FK506 treatment increases dendritic branching and dendritic spine density in healthy adult mouse brain
resolves10.1016/j.nbd.2010.11.014
Calcineurin inhibition with FK506 ameliorates dendritic spine density deficits in plaque-bearing Alzheimer model mice
resolves10.1523/JNEUROSCI.6439-11.2012
Inhibition of the NFAT Pathway Alleviates Amyloid Beta Neurotoxicity in a Mouse Model of Alzheimer's Disease
resolves10.1523/JNEUROSCI.0365-05.2005
Calcineurin Triggers Reactive/Inflammatory Processes in Astrocytes and Is Upregulated in Aging and Alzheimer's Models
resolves10.1523/JNEUROSCI.1064-09.2009
Cognitive Decline in Alzheimer's Disease Is Associated with Selective Changes in Calcineurin/NFAT Signaling
resolves10.1523/JNEUROSCI.0877-17.2017
Calcineurin/NFAT Signaling in Activated Astrocytes Drives Network Hyperexcitability in Aβ-Bearing Mice
resolves10.1111/jnc.14469
Neuronal calcineurin transcriptional targets parallel changes observed in Alzheimer disease brain
resolves10.1210/en.2011-2149
Increased Expression of the Glucose-Responsive Gene, RCAN1, Causes Hypoinsulinemia, β-Cell Dysfunction, and Diabetes
resolves10.1371/journal.pgen.1006033
A Syntenic Cross Species Aneuploidy Genetic Screen Links RCAN1 Expression to β-Cell Mitochondrial Dysfunction in Type 2 Diabetes
resolves10.3233/JAD-2006-9305
Gene expression alterations in brain areas of intracerebroventricular streptozotocin treated rat
resolves10.1111/j.1471-4159.2005.03637.x
Alzheimer‐like changes in protein kinase B and glycogen synthase kinase‐3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway
resolves10.1016/j.bbr.2012.12.005
Intracerebroventricular administration of an insulin analogue recovers STZ-induced cognitive decline in rats
resolves10.3233/JAD-151013
T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer’s Disease
resolves10.1172/JCI59903
Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline
resolves10.1126/science.8346443
Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families
resolves10.1016/S0140-6736(96)09328-2
Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study
resolves10.1212/WNL.46.3.673
Apolipoprotein E element 4 association with dementia in a population-based study
resolves10.1073/pnas.90.5.1977
Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.
resolves10.1186/1471-2458-14-643
Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis
resolves10.1111/1754-9485.12115
Prospective study of exercise intervention in prostate cancer patients on androgen deprivation therapy
resolves10.1016/j.metabol.2009.10.007
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients
resolves10.1016/j.exger.2010.08.026
Intranasal insulin as a therapeutic option in the treatment of cognitive impairments
resolves10.3233/JAD-141791
Long-Acting Intranasal Insulin Detemir Improves Cognition for Adults with Mild Cognitive Impairment or Early-Stage Alzheimer's Disease Dementia
resolves10.1517/17425247.2013.856877
Intranasal insulin therapy for cognitive impairment and neurodegeneration: current state of the art
resolves10.1007/s40263-013-0076-8
Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence
resolves10.1016/j.neurobiolaging.2005.03.016
Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype
resolves10.1155/NP.2005.311
The Role of Insulin, Insulin Growth Factor, and Insulin‐Degrading Enzyme in Brain Aging and Alzheimer′s Disease
resolves10.1001/archneurol.2010.225
Insulin Resistance and Alzheimer-like Reductions in Regional Cerebral Glucose Metabolism for Cognitively Normal Adults With Prediabetes or Early Type 2 Diabetes
resolves10.1016/j.neuroscience.2012.10.045
The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer’s disease
resolves10.1097/01.wad.0000213866.86934.7e
Insulin Resistance Syndrome and Alzheimer Disease: Pathophysiologic Mechanisms and Therapeutic Implications
resolves10.2174/156720507780362137
Insulin Resistance and Alzheimers Disease Pathogenesis: Potential Mechanisms and Implications for Treatment
resolves10.3233/JAD-180906
Early-Stage Alzheimer’s Disease Is Associated with Simultaneous Systemic and Central Nervous System Dysregulation of Insulin-Linked Metabolic Pathways
resolves10.1093/alcalc/agv102
Differential Contributions of Alcohol and Nicotine-Derived Nitrosamine Ketone (NNK) to White Matter Pathology in the Adolescent Rat Brain
resolves10.1111/j.1872-034X.2011.00934.x
High fat diet induced hepatic steatosis and insulin resistance: Role of dysregulated ceramide metabolism
resolves10.1111/j.1582-4934.2011.01318.x
Possible implications of insulin resistance and glucose metabolism in Alzheimer’s disease pathogenesis
resolves10.2174/156720508785908919
Insulin Resistance and Alzheimers Disease: Molecular Links & Clinical Implications
resolves10.3233/JAD-122308
Sex and ApoE Genotype Differences in Treatment Response to Two Doses of Intranasal Insulin in Adults with Mild Cognitive Impairment or Alzheimer's Disease
resolves10.2217/ahe.11.89
Early Intranasal Insulin Therapy Halts Progression of Neurodegeneration: Progress in Alzheimer’s Disease Therapeutics
resolves10.1212/01.WNL.0000265401.62434.36
Intranasal insulin improves cognition and modulates β-amyloid in early AD
resolves10.1016/j.neurobiolaging.2004.06.013
Age- and region-dependent alterations in Aβ-degrading enzymes: implications for Aβ-induced disorders
resolves10.1111/j.1742-4658.2007.05717.x
RCAN1‐1L is overexpressed in neurons of Alzheimer's disease patients
resolves10.1016/j.bbadis.2014.04.007
Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain
resolves10.1007/s12035-015-9576-5
Inhibitory Effect of Memantine on Streptozotocin-Induced Insulin Receptor Dysfunction, Neuroinflammation, Amyloidogenesis, and Neurotrophic Factor Decline in Astrocytes
resolves10.1186/1750-1326-9-16
Increased mtDNA mutations with aging promotes amyloid accumulation and brain atrophy in the APP/Ld transgenic mouse model of Alzheimer’s disease
resolves10.2174/156720509789207949
A PPARdelta Agonist Reduces Amyloid Burden and Brain Inflammation in a Transgenic Mouse Model of Alzheimers Disease
resolves10.1016/S0304-3940(02)00586-4
Polymorphisms of insulin degrading enzyme gene are not associated with Alzheimer's disease
resolves10.1016/j.neurobiolaging.2008.09.016
Differential cerebral deposition of IDE and NEP in sporadic and familial Alzheimer's disease
resolves10.1371/journal.pone.0008764
Concordant Association of Insulin Degrading Enzyme Gene (IDE) Variants with IDE mRNA, Aß, and Alzheimer's Disease
resolves10.1016/j.neulet.2008.04.025
Increased expression of Aβ degrading enzyme IDE in the cortex of transgenic mice with Alzheimer's disease-like neuropathology
resolves10.1007/BF03346691
Impaired amyloid β-degrading enzymes in brain of streptozotocin-induced diabetic rats
resolves10.1007/s10522-015-9569-9
Effects of ageing and experimental diabetes on insulin-degrading enzyme expression in male rat tissues
resolves10.1016/j.neulet.2012.08.071
TGF-β induced by interleukin-34-stimulated microglia regulates microglial proliferation and attenuates oligomeric amyloid β neurotoxicity
resolves10.1002/glia.21079
Response of transcription factor NFATc3 to excitotoxic and traumatic brain insults: Identification of a subpopulation of reactive astrocytes
resolves10.1002/glia.20647
Calcium/calcineurin signaling in primary cortical astrocyte cultures: Rcan1‐4 and cyclooxygenase‐2 as NFAT target genes
resolves10.3233/JAD-2012-120973
Lymphocytes from Young Healthy Persons Carrying the ApoE4 Allele Overexpress Stress-Related Proteins Involved in the Pathophysiology of Alzheimer's Disease
resolves10.1016/j.neurobiolaging.2006.06.017
Positive association between risk for late-onset Alzheimer disease and genetic variation in IDE
resolves10.1016/j.brainres.2008.10.034
Promoter polymorphisms which modulate insulin degrading enzyme expression may increase susceptibility to Alzheimer's disease
resolves10.1186/1471-2350-12-151
Disorder-specific effects of polymorphisms at opposing ends of the Insulin Degrading Enzymegene
resolves10.1002/humu.10282
Genetic variation in a haplotype block spanningIDE influences Alzheimer disease
The 10 references without a DOI — listed, not checked
no DOI — not checkedInsulin‐degrading enzyme
no DOI — not checkedThe inactivation of insulin by tissue extracts; the distribution and properties of insulin inactivating extracts
no DOI — not checkedOligodendroglial and neuroglial molecular abnormalities in the intracerebral streptozotocin model of sporadic Alzheimer's disease
no DOI — not checkedAlzheimer's disease, amnestic mild cognitive impairment, and age‐associated memory impairment: current understanding and progress toward integrative prevention
no DOI — not checkedPhysical exercise and cognitive performance in the elderly: current perspectives
no DOI — not checkedAltered serum and cerebrospinal fluid inflammatory cascades in mild cognitive impairment and Alzheimer's disease
no DOI — not checkedCSF and brain indices of insulin resistance, oxidative stress and neuro‐inflammation in early versus late Alzheimer's disease
no DOI — not checkedInsulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer's disease: Possible mechanisms of IDE in T2D and AD
no DOI — not checkedDesensitization of brain insulin receptor. Effect on glucose/energy and related metabolism
no DOI — not checkedMetabolic derangements mediate cognitive impairment and Alzheimer's disease: Role of peripheral insulin‐resistance diseases
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1016/j.dadm.2019.03.004"><img src="https://citestamp.com/citestamped/10.1016/j.dadm.2019.03.004/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1016/j.dadm.2019.03.004)